Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer—Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2024.08.007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von John J Coen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Roger Williams Radiation Oncology, Providence, Rhode Island. Electronic address: jcoen1@me.com. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Gemcitabine, Deoxycytidine, Cisplatin. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE: For bladder-sparing treatment of muscle-invasive bladder cancer, 5-fluorouracil/cisplatin with twice-daily radiation (FCT) or gemcitabine plus daily radiation (GD) are effective chemoradiation (CRT) regimens. This trial evaluated these regimens and demonstrated efficacy with either regimen at 3 years. With further follow-up, longer-term results are reported here. METHODS AND MATERIALS: Patients with cT2 to cT4a muscle-invasive bladder cancer were randomized to FCT or GD. Patients had a transurethral resection and induction CRT to 40 Gy. Patients with a complete response received consolidation CRT to 64 Gy. Others had cystectomy. Adjuvant gemcitabine/cisplatin chemotherapy was administered. The primary endpoint was freedom from distant metastasis (FDM). This updated analysis reports 7-year data. Toxicity and efficacy endpoints, including bladder-intact distant metastasis-free survival (BI-DMFS) were also assessed. RESULTS: From December 2008 to April 2014, 70 patients were enrolled; 66 were eligible for analysis, 33 per arm. Median follow-up was 9.1 years for eligible living patients. At 7 years, FDM was 65% and 73% for FCT and GD, respectively. Bladder-intact distant metastasis-free survival was 58% (95% CI, 41-76) and 68% (95% CI, 51-84), respectively. The post hoc hazard ratio of 0.75 (95% CI, 0.37-1.55) showed no difference between treatments (P = .44). Overall survival at 7 years was 48% and 59%. There were 4 and 5 cystectomies performed for FCT and GD, respectively. In the FCT arm, there were 5 (16%), 1 (3%), and 0 grade 3, 4, and 5 late toxicities reported, respectively. In the GD arm, there were 7 (23%), 0, and 0 grade 3, 4, and 5 late toxicities reported, respectively. CONCLUSIONS: Both regimens maintained high FDM rates at 7 years. Cystectomy rates were low and overall survival rates were high on both arms. Late toxicity rates were low. Either gemcitabine and daily radiation or a cisplatin-based regimen are effective bladder-sparing therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Roger Williams Radiation Oncology, Providence, Rhode Island. Electronic address: jcoen1@me.com.
- NRG Oncology Statistics and Data Management Center - American College of Radiology, Philadelphia, Pennsylvania.
- Massachusetts General Hospital, Boston, Massachusetts.
- Ohio State University Comprehensive Center, Columbus, Ohio.
- McGill University Health Centre, Montreal, Quebec, Canada.
- Indiana University, Indianapolis, Indiana.
Förderung
- NCI NIH HHS
Zitieren
APA
Coen, J. J., Rodgers, J. P., Saylor, P. J., Lee, C. T., Wu, C. L., Parker, W., Lautenschlaeger, T., Zietman, A. L., Efstathiou, J., Jani, A. B., Kucuk, O., Souhami, L., Pugh, S. L., Sandler, H. M., & Shipley, W. U. (2025). Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer—Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.08.007
Vancouver
Coen JJ, Rodgers JP, Saylor PJ, Lee CT, Wu CL, Parker W, et al. Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer—Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2024.08.007
BibTeX
@article{Coen2025,
author = {Coen, John J and Rodgers, Joseph P and Saylor, Philip J and Lee, Cheryl T and Wu, Chin-Lee and Parker, William and Lautenschlaeger, Tim and Zietman, Anthony L and Efstathiou, Jason and Jani, Ashesh B and Kucuk, Omer and Souhami, Luis and Pugh, Stephanie L and Sandler, Howard M and Shipley, William U},
title = {Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer—Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2024.08.007}
}
EUVIMED